EP2393473A1 - Système d'administration buccale contenant du 17a-oestradiol - Google Patents
Système d'administration buccale contenant du 17a-oestradiolInfo
- Publication number
- EP2393473A1 EP2393473A1 EP10702616A EP10702616A EP2393473A1 EP 2393473 A1 EP2393473 A1 EP 2393473A1 EP 10702616 A EP10702616 A EP 10702616A EP 10702616 A EP10702616 A EP 10702616A EP 2393473 A1 EP2393473 A1 EP 2393473A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- estradiol
- application system
- dose
- treatment
- women
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 title claims abstract description 33
- 206010060800 Hot flush Diseases 0.000 claims abstract description 15
- 208000033830 Hot Flashes Diseases 0.000 claims abstract description 11
- 206010030247 Oestrogen deficiency Diseases 0.000 claims abstract description 7
- 229930182834 17alpha-Estradiol Natural products 0.000 claims description 31
- 208000024891 symptom Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000227 bioadhesive Substances 0.000 claims description 4
- 238000009806 oophorectomy Methods 0.000 claims description 4
- 230000009245 menopause Effects 0.000 claims description 2
- 239000000654 additive Substances 0.000 abstract description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 13
- 229940011871 estrogen Drugs 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 9
- 229960005309 estradiol Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002657 hormone replacement therapy Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000005186 women's health Effects 0.000 description 2
- ZVVGLAMWAQMPDR-WVEWYJOQSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;hydrate Chemical compound O.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 ZVVGLAMWAQMPDR-WVEWYJOQSA-N 0.000 description 1
- RYWZPRVUQHMJFF-KSZLIROESA-N 17alpha-Dihydroequilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CC[C@H]3O)C)=C4C=CC2=C1 RYWZPRVUQHMJFF-KSZLIROESA-N 0.000 description 1
- RYWZPRVUQHMJFF-UHFFFAOYSA-N 17alpha-Dihydroequilenin Natural products OC1=CC=C2C(CCC3(C4CCC3O)C)=C4C=CC2=C1 RYWZPRVUQHMJFF-UHFFFAOYSA-N 0.000 description 1
- 206010003439 Artificial menopause Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229960003851 estradiol hemihydrate Drugs 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Definitions
- the invention relates to an application system for the buccal administration of 17 ⁇ -estradiol for the treatment of hot flashes in women with natural (climacteric) or surgically induced (ovariectomy) estrogen deficiency symptoms.
- the 17 ⁇ -estradiol is used in a low dosage at 50 to 400 ⁇ g, preferably 200 to 400 ⁇ g, more preferably 300 ⁇ g together with one or more pharmaceutically acceptable excipients / carriers.
- HRT Classical hormone replacement therapy
- 17 ⁇ -estradiol is the naturally occurring epimer of 17ß-estradiol and differs only in its stereochemistry at the carbon atom 17. In humans, it is detectable only in very low concentrations and its physiological role is unclear. Significantly higher concentrations can be found in the animal kingdom, in particular in the urine of pregnant mares (Husmann F. The effects of 17 ⁇ -estrogens I. part: Klan, Horme 2003; 16: 1-8). 17 ⁇ -Estradiol is about 3.7% (Washbum SA et al., Effects of 17 ⁇ -dihydroequilenin sulfate on atherosclerotic male and female rhesus monkeys., J.
- Obstet Gynecol 1996; 175: 341-51) is used in this form for about 50 years for the treatment of menopausal symptoms in humans (but in a mixture with a variety of other substances with estrogenic effect). It shows an approximately 5-fold weaker binding affinity and an at least 200-fold weaker effect on the estrogen receptor in the transactivation assay than 17 ⁇ -estradiol and is therefore to be characterized as a weak estrogen. At the same time, due to its chemical structure, as well as 17 ⁇ -estradiol, it has a number of non-genomic effects which have been considered for drug development.
- 17 ⁇ -estradiol is suitable as a monosubstance for the treatment of hot flushes in both post-menopausal women and younger patients after removal of both ovaries. This result was not close to the state of the art because 17 ⁇ -estradiol, as stated, is a weak estrogen and has only a low binding capacity at the estrogen receptor.
- European Patent EP 1 032 398 B1 is directed to the treatment of postmenopausal women using lowest estrogen doses, such as less than 0.5 mg. The treatment of heat rolls is listed here. European Patent EP 1 539 1 84 B1 discloses an estrogen therapy containing different dosages in different phases.
- WO 2006/048261 discloses a solid oral dosage form containing an amount therapeutically equivalent to 0, 01-0.5 mg estradiol hemihydrate.
- WO 2007/1 191 51 discloses the reduction of menopausal symptoms in female patients, such as hot flashes, with a daily estradiol dose of 0.25-0.42 mg. DESCRIPTION OF THE INVENTION The object of the present invention was to provide a possibility for
- the object underlying the present invention was achieved by providing an application system for the buccal administration of 1 7 ⁇ -estradiol for the treatment of hot flashes in women with natural (climacteric) or surgically induced (ovariectomy) estrogen deficiency symptoms.
- 17 ⁇ -estradiol in a low dosage to 50 to 400 micrograms, preferably 200 to 400 micrograms, more preferably 300 micrograms used together with one or more pharmaceutically acceptable excipients / carriers.
- the invention surprisingly claims a buccal administration form based on a bioadhesive tablet.
- This bioadhesive tablet allows absorption of the drug already in the oral cavity with increased bioavailability and avoidance of the hepatic first-pass effect, d. H. In the present patent application, this is done by means of 17 ⁇ -estradiol in low dosage for the treatment of hot flashes. It may be dispensed with a gestagen additive, so that may occur no adverse effects on the chest.
- Example 1 Example 1
- Example 2 All substances are mixed and granulated in a suitable manner, and after completion of the granulation process, tableting is carried out.
- Example 2 All substances are mixed and granulated in a suitable manner, and after completion of the granulation process, tableting is carried out.
- All substances are mixed and granulated in a suitable manner, and after completion of the granulation process, tableting is carried out.
- the buccal administration system preferably dissolves in the oral cavity in a period of less than 180 minutes, more preferably in a period of less than 120 minutes.
- the 17 ⁇ -estradiol entering the bloodstream directly from the administration system leads to a rapid increase in the concentration of 17 ⁇ -estradiol in the blood.
- a maximum of the concentration of 17 ⁇ -estradiol in the blood is preferably achieved within a period of less than 60 minutes, particularly preferably within a period of between 30 and 60 minutes, after application.
- Characteristic of the application system according to the invention is the high bioavailability of the 17 ⁇ -estradiol and the uptake of the active ingredient already in the oral cavity, so that a first-pass effect is avoided and high plasma levels are achieved. It can be achieved with the buccal administration system, a bioavailability of at least 80%. In a particularly preferred embodiment, the 17 ⁇ -estradiol is released with a bioavailability of 70 to 90%
- endometrial thickness was measured by transvaginal ultrasound examinations.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention porte sur des systèmes d'administration buccale, contenant du 17a-oestradiol à une dose de 50 à 400 µg, de préférence de 200 à 400 µg, d'une manière particulièrement préférée de 300 µg, en même temps qu'un ou plusieurs adjuvants/supports pharmaceutiquement acceptables, ces systèmes réalisant un traitement/une réduction minimum des bouffées de chaleur chez les femmes présentant des phénomènes de carence en oestrogènes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009007771A DE102009007771B4 (de) | 2009-02-05 | 2009-02-05 | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
| PCT/EP2010/000619 WO2010089078A1 (fr) | 2009-02-05 | 2010-02-02 | Système d'administration buccale contenant du 17α-oestradiol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2393473A1 true EP2393473A1 (fr) | 2011-12-14 |
Family
ID=42077003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10702616A Withdrawn EP2393473A1 (fr) | 2009-02-05 | 2010-02-02 | Système d'administration buccale contenant du 17a-oestradiol |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120142656A1 (fr) |
| EP (1) | EP2393473A1 (fr) |
| JP (1) | JP2012516859A (fr) |
| CA (1) | CA2751399A1 (fr) |
| DE (1) | DE102009007771B4 (fr) |
| RU (1) | RU2011136043A (fr) |
| WO (1) | WO2010089078A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2714712T (pt) | 2011-06-01 | 2016-11-08 | Estetra Sprl | Processo para a produção de intermediários de estetrol |
| SG195118A1 (en) | 2011-06-01 | 2013-12-30 | Estetra S A | Process for the production of estetrol intermediates |
| EP2383279A1 (fr) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Procédé de préparation d'estetrol |
| GB201200062D0 (en) | 2012-01-04 | 2012-02-15 | Innotesto Bvba | Estradiol oromucosal liquid compositions |
| JP6447931B2 (ja) * | 2013-12-12 | 2019-01-09 | ドネスタ バイオサイエンス ビー．ブイ．Ｄｏｎｅｓｔａ Ｂｉｏｓｃｉｅｎｃｅ Ｂ．Ｖ． | エステトロール成分を含有する口腔内崩壊固体単位剤形 |
| LT3310346T (lt) | 2015-06-18 | 2021-06-10 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| CR20180042A (es) | 2015-06-18 | 2018-05-03 | Mithra Pharmaceuticals S A | Unidad de dosificación orodispersable que contiene un componente estetrol. |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| DK3701944T3 (da) | 2015-06-18 | 2022-03-14 | Estetra Srl | Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| CN111989105B (zh) | 2018-04-19 | 2024-07-19 | 埃斯特拉私人有限责任公司 | 化合物以及它们在缓解绝经相关症状中的用途 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1306950C (fr) * | 1987-04-10 | 1992-09-01 | Alec D. Keith | Administration d'oestrogenes par voie orale |
| US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
| US5891868A (en) | 1997-11-21 | 1999-04-06 | Kaiser Foundation Health Plan, Inc. | Methods for treating postmenopausal women using ultra-low doses of estrogen |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| AU2003264203A1 (en) | 2002-08-28 | 2004-03-19 | Robert Casper | Estrogen replacement regimen |
| DE102004023984A1 (de) * | 2004-05-14 | 2005-12-08 | Hf Arzneimittelforschung Gmbh | Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol |
| GT200500315A (es) | 2004-11-02 | 2006-06-06 | Formas de dosificacion oral solidas que contienen una dosis baja de estradiol | |
| US20070254036A1 (en) | 2006-04-13 | 2007-11-01 | Besins Healthcare Sa | Treatment of menopause associated symptoms |
| DE102006027796A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Estrogen-Gestagen-Kombinationen |
-
2009
- 2009-02-05 DE DE102009007771A patent/DE102009007771B4/de not_active Withdrawn - After Issue
-
2010
- 2010-02-02 WO PCT/EP2010/000619 patent/WO2010089078A1/fr not_active Ceased
- 2010-02-02 US US13/148,300 patent/US20120142656A1/en not_active Abandoned
- 2010-02-02 JP JP2011548587A patent/JP2012516859A/ja active Pending
- 2010-02-02 EP EP10702616A patent/EP2393473A1/fr not_active Withdrawn
- 2010-02-02 CA CA2751399A patent/CA2751399A1/fr not_active Abandoned
- 2010-02-02 RU RU2011136043/15A patent/RU2011136043A/ru not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2010089078A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE102009007771A1 (de) | 2010-08-19 |
| RU2011136043A (ru) | 2013-03-10 |
| JP2012516859A (ja) | 2012-07-26 |
| US20120142656A1 (en) | 2012-06-07 |
| DE102009007771B4 (de) | 2012-02-16 |
| WO2010089078A1 (fr) | 2010-08-12 |
| CA2751399A1 (fr) | 2010-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE102009007771B4 (de) | Bukkales Applikationssystem, 17α-Estradiol enthaltend | |
| EP1011682B1 (fr) | Moyen de contraception hormonale | |
| DE68928897T2 (de) | Verfahren und system zur empfängnisverhütung | |
| DE69427529T2 (de) | Hormon-ersatztherapie | |
| EP0735883B1 (fr) | Composition contraceptive comprenant un estrogene et un gestagene | |
| EP2552404B1 (fr) | Forme galénique parentérale libérant des inhibiteurs de l'aromatase et des gestagènes, pour le traitement de l'endométriose | |
| DE60203929T2 (de) | Behandlungsverfahren und pharmazeutische zusammensetzung zur notfall-empfängnisverhütung | |
| DE69729956T2 (de) | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält | |
| DE19705229A1 (de) | Mittel zur hormonalen Kontrazeption | |
| WO1996019997A1 (fr) | Composes a action antagoniste de la progesterone et anti×strogene utilisees conjointement pour la contraception feminine | |
| EP1978970B1 (fr) | Agent contraceptif | |
| EP2059248A1 (fr) | Préparation pharmaceutique conçue pour traiter une endométriose | |
| EP1978969A1 (fr) | Médicament comprenant une association d'hormones | |
| EP1753435A1 (fr) | Utilisation d'une association d'ethinylestradiol et d'acetate de chlormadinone pour produire un medicament | |
| EP2194978A1 (fr) | Utilisation de gestagènes en combinaison avec du (6s)-5-méthyltétrahydrofolate pour le traitement de l'endométriose avec réduction simultanée d'effets secondaires du traitement et diminution du risque de malformations congénitales en début de grossesse | |
| EP1853273A1 (fr) | Composition pharmaceutique destinée à la contraception | |
| DE102008033254B4 (de) | Verfahren zur Herstellung eines einphasischen pharmazeutischen Präparates zur oralen Therapie der Regulierung des Blutdruckes | |
| EP1655031A1 (fr) | Utilisation de dienogest pour contraceptives hormonelles avec cycle prolongué | |
| DE202009016374U1 (de) | Formulierung für Frauen im Klimakterium, in der chirurgisch bedingten Menopause oder während einer GnRH-Behandlung | |
| WO2009015766A1 (fr) | Préparation pharmaceutique combinée monophasique (diénogest et éthinylestradiol) pour la thérapie orale de régulation de la pression artérielle | |
| WO2006013464A1 (fr) | Thérapie de remplacement hormonal comprenant une combinaison de 17bêta-estradiol et d’acétate de chlormadinone | |
| DE19635883A1 (de) | Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination | |
| WO1996029078A1 (fr) | AGENT INHIBITEUR D'OVULATION POUR CONTRACEPTION HORMONALE CONTENANT 50 A 70 νg DE LEVONORGESTREL ET PLUS DE 30 A 40 νg D'ETHINYLESTRADIOL | |
| WO2007059918A1 (fr) | Utilisation d'une association d'éthinylestradiol et d'acétate de chlormadinone pour le traitement de troubles de l'humeur |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20110905 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20140902 |